Adjuvant Treatment of HR Positive HER2 Negative EBC

CE / CME

Integrating the Evidence on Adjuvant Therapy for High-risk HR-Positive/HER2-Negative Early Breast Cancer

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Nurses: 0.50 Nursing contact hour

Pharmacists: 0.50 contact hour (0.05 CEUs)

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

ABIM MOC: maximum of 0.50 Medical Knowledge MOC point

Released: February 05, 2025

Expiration: February 04, 2026

Activity

Progress
1 2
Course Completed

References

  1. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: breast cancer. v1.2025. nccn.org. Accessed February 4, 2025.
  2. Kalinsky K, Barlow WE, Gralow JR, et al. 21-Gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 2021;385:2336-2347.
  3. Kalinsky K, Barlow WE, Pathak HB, et al. Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER). Presented at: 40th Annual Meeting of the American Society of Clinical Oncology; June 5-8, 2004. Abstract 505.
  4. Abemaciclib [prescribing information]. Indianapolis, IN: Eli Lilly and Company; 2024.
  5. Ribociclib [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2024.
  6. Rastogi P, O'Shaughnessy J, Martin M, et al. Adjuvant abemaciclib plus endocrine therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes. J Clin Oncol. 2024;42:987-993.
  7. Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020;38:3987-3998.
  8. Slamon D, Lipatov O, Nowecki Z, et al. Ribociclib plus endocrine therapy in early breast cancer. N Engl J Med. 2024;390:1080-1091.
  9. Fasching PA, Stroyakovskiy D, Yardley D, et al. Adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients (Pts) with HR+/HER2− early breast cancer (EBC): 4-year outcomes from the NATALEE trial. Presented at: European Society for Medical Oncology Congress; September 13-17, 2024. Abstract LBA13.
  10. Johnston SRD, Toi M, O’Shaughnessy J, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24:77-90.
  11. Rugo HS, O'Shaughnessy J, Boyle F, et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study. Ann Oncol. 2022;33:616-627.
  12. Fasching PA, Slamon D, Nowecki Z, et al. Health-related quality of life (HRQoL) in the phase III NATALEE study of adjuvant ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) vs NSAI alone in patients (pts) with HR+/HER2− early breast cancer (EBC). Presented at: European Society for Medical Oncology Congress; October 20-24, 2023. Abstract VP3-2023.
  13. Tolaney SM, Guarneri V, Seo JH, et al. Long-term patient-reported outcomes from monarchE: abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer. Eur J Cancer. 2024;199:113555.
  14. Goetz MP, Cicin I, Testa L, et al. Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study. NPJ Breast Cancer. 2024;10:34.
  15. O’Shaughnessy J, Cicin I, Testa L, et al. Impact of dose reductions on efficacy of adjuvant abemaciclib for patients with high-risk early breast cancer (EBC): analyses from the monarchE study. Presented at: European Society for Medical Oncology Congress; October 20-24, 2023. Abstract 274P.
  16. Barrios C, Harbeck N, Hortobagyi G, et al. NATALEE update: safety and treatment (tx) duration of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAID) in patients (pts) with HR+/HER2- early breast cancer (EBC). Presented at: European Society for Medical Oncology Breast Cancer Congress; May 15-17, 2024. Abstract 113MO.
  17. Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021;384:2394-2405.
  18. Geyer CE Jr, Garber JE, Gelber RD, et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol. 2022;33:1250-1268.
  19. Garber J. OlympiA: a phase 3, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients w/ germline BRCA1 and BRCA2 pathogenic variants and high risk HER2-negative primary breast cancer: longer-term follow-up. Presented at: San Antonio Breast Cancer Symposium; December 10-13, 2024. Abstract GS1-09.
  20. Olaparib [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals; 2023.
  21. National Comprehensive Cancer Network. Genetic/familial high-risk assessment: breast, ovarian, pancreatic, and prostate. v2.2025. nccn.org. Accessed February 4, 2025.
  22. Bedrosian I, Somerfield MR, Achatz MI, et al. Germline testing in patients with breast cancer: ASCO-Society of Surgical Oncology Guideline. J Clin Oncol. 2024;42:584-604.